Cargando…
Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
Historically, research and development (R&D) in the pharmaceutical sector has predominantly been an in-house activity. To enable investments for game changing late-stage assets and to enable better and less costly go/no-go decisions, most companies have employed a fail early paradigm through the...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941640/ https://www.ncbi.nlm.nih.gov/pubmed/29739427 http://dx.doi.org/10.1186/s12967-018-1499-2 |